Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Associations between homocysteine metabolism related SNPs and carotid intima-media thickness: a Chinese sib pair study.

Sun K, Song J, Liu K, Fang K, Wang L, Wang X, Li J, Tang X, Wu Y, Qin X, Wu T, Gao P, Chen D, Hu Y.

J Thromb Thrombolysis. 2017 Apr;43(3):401-410. doi: 10.1007/s11239-016-1449-x.

2.

Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in Diabetes and the Metabolic Syndrome.

Heinl RE, Dhindsa DS, Mahlof EN, Schultz WM, Ricketts JC, Varghese T, Esmaeeli A, Allard-Ratick MP, Millard AJ, Kelli HM, Sandesara PB, Eapen DJ, Sperling L.

Can J Cardiol. 2016 Oct;32(10S2):S349-S357. doi: 10.1016/j.cjca.2016.07.507. Epub 2016 Jul 22. Review.

3.

A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice.

Piao L, Jung I, Huh JY, Miyata T, Ha H.

Br J Pharmacol. 2016 Sep;173(17):2622-32. doi: 10.1111/bph.13541. Epub 2016 Jul 28.

PMID:
27339909
4.

Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus.

Canecki-Varžić S, Prpić-Križevac I, Bilić-Ćurčić I.

BMC Endocr Disord. 2016 Mar 3;16:14. doi: 10.1186/s12902-016-0094-x.

5.

A closer look at the role of urotensin II in the metabolic syndrome.

Barrette PO, Schwertani AG.

Front Endocrinol (Lausanne). 2012 Dec 28;3:165. doi: 10.3389/fendo.2012.00165. eCollection 2012.

6.

Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients.

Nomura S, Taniura T, Shouzu A, Omoto S, Inami N, Fujita S, Tamaki T, Yokoi T, Shimizu T, Ito T.

Int J Gen Med. 2012;5:535-40. doi: 10.2147/IJGM.S31346. Epub 2012 Jun 18.

7.

Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD 3rd, Schneider DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL; BARI 2D Investigators..

Circulation. 2011 Aug 9;124(6):695-703. doi: 10.1161/CIRCULATIONAHA.110.014860. Epub 2011 Jul 18.

8.

Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies.

Voulgari C, Papadogiannis D, Tentolouris N.

Vasc Health Risk Manag. 2010 Oct 21;6:883-903. doi: 10.2147/VHRM.S11681. Review.

9.

Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Cesari M, Pahor M, Incalzi RA.

Cardiovasc Ther. 2010 Oct;28(5):e72-91. doi: 10.1111/j.1755-5922.2010.00171.x. Epub 2010 Jul 7. Review.

10.

Relevance of hemostatic risk factors on coronary morphology in patients with diabetes mellitus type 2.

Jax TW, Peters AJ, Plehn G, Schoebel FC.

Cardiovasc Diabetol. 2009 May 6;8:24. doi: 10.1186/1475-2840-8-24.

11.

Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis.

Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R.

Diabetes Care. 2009 Feb;32(2):361-6. doi: 10.2337/dc08-0854. Epub 2008 Nov 18.

12.

Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.

Wang L, Rockwood J, Zak D, Devaraj S, Jialal I.

Metab Syndr Relat Disord. 2008 Jun;6(2):149-52. doi: 10.1089/met.2008.0012.

13.

WRN polymorphisms affect expression levels of plasminogen activator inhibitor type 1 in cultured fibroblasts.

Castro E, Oviedo-Rodríguez V, Angel-Chávez LI.

BMC Cardiovasc Disord. 2008 Feb 29;8:5. doi: 10.1186/1471-2261-8-5.

14.

Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.

Nordstrom SM, Carleton SM, Carson WL, Eren M, Phillips CL, Vaughan DE.

Bone. 2007 Dec;41(6):995-1004. Epub 2007 Aug 17.

15.

Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas.

Hoshino M, Haraguchi Y, Hirasawa H, Sakai M, Saegusa H, Hayashi K, Horita N, Ohsawa H.

Crit Care. 2001;5(2):88-99. Epub 2001 Feb 26.

16.

Insulin resistance and cardiovascular disease.

Ginsberg HN.

J Clin Invest. 2000 Aug;106(4):453-8. Review. No abstract available.

17.
18.

Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles.

Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM.

J Clin Invest. 1993 Jul;92(1):141-6.

19.

Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D.

J Clin Invest. 1993 Dec;92(6):2756-60.

20.

Avoiding premature coronary deaths in Asians in Britain.

Gupta S, de Belder A, Hughes LO.

BMJ. 1995 Oct 21;311(7012):1035-6. No abstract available.

Supplemental Content

Support Center